Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06734741 · ClinicalTrials.gov registry record

Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use

A clinical trial, sponsored by InBios International.

Completed
Registry status
899
Enrollment target

NCT06734741 is a clinical trial that has completed, run by InBios International. The registered enrollment target is 899 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06734741 has completed, sponsored by InBios International.

COMPLETED
Registry status
899 participants
Enrollment target

Study Summary

The goal of this study is to evaluate the performance of the COVID/Flu Detect™ Rapid Self-Test when used in a home-like setting by lay users. The COVID/Flu Detect™ Rapid Self-Test is an investigational device intended for the qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens in nasal swab samples. Participants who are aged two (2) years and older and have symptoms of respiratory illness consistent with SARS-CoV-2 and influenza infection may be enrolled. Participants will use the COVID/Flu Detect™ Rapid Self-Test to self-collect, self-test, and interpret the results. Participants will have a nasal swab sample collected by a healthcare provider for comparator testing by PCR tests for SARS-CoV-2, influenza A, and influenza B. Researchers will compare the results of the COVID/Flu Detect™ Rapid Self-Test obtained by the participants to results from the PCR comparator tests to evaluate performance.

Interventions

  • DIAGNOSTIC_TEST COVID/Flu Detect™ Rapid Self-Test

Trial Details

FieldValue
Enrollment Target 899 participants
Start Date 2024-12-26
Est. Completion 2025-05-19

Sponsor

InBios International

5 total trials

What the Registry Record Tells You About NCT06734741

The ClinicalTrials.gov registry entry for NCT06734741 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 899 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InBios International, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which COVID/Flu Detect™ Rapid Self-Test is the first listed.

NCT06734741 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06734741 about?

NCT06734741 is a clinical study titled "Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use". The goal of this study is to evaluate the performance of the COVID/Flu Detect™ Rapid Self-Test when used in a home-like setting by lay users. The COVID/Flu Detect™ Rapid Self-Test is an investigational device intended for the qualitative detection and differentiation of SARS-CoV-2, influenza A, and ...

What is the current status of trial NCT06734741?

This trial is currently completed. The enrollment target is 899 participants. The study started on 2024-12-26. Estimated completion is 2025-05-19.

What interventions are being tested in trial NCT06734741?

The interventions under investigation include: COVID/Flu Detect™ Rapid Self-Test (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06734741?

This trial is sponsored by InBios International, which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.